Sign in
Taking people in NetherlandsPhase 1

Tests how a drug enters tumours in people with lung or neuroendocrine cancer

Tests BI 764532 in adults with small-cell lung cancer or related neuroendocrine cancers.

Key facts

Who runs it
Boehringer Ingelheim International GmbH
Where
Amsterdam, NetherlandsSee the site
Trial code
Registry title
A study to test how BI 764532 is taken up by tumours in people with small-cell lung cancer or neuroendocrine cancer
Status
Recruiting
Phase
Phase 1
People taking part
12 people, planned
Started
22 Feb 2024
Expected to end
25 Nov 2026
Type of study
Interventional
Record updated
15 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with small-cell lung cancer or neuroendocrine cancer. It tests how the study drug BI 764532 is taken up by tumours.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC) or small cell carcinoma of any other origin, or large cell neuroendocrine lung carcinoma (LCNEC).

Main reasons for not taking part

  • Healthy volunteers cannot join.

Where in Netherlands

  • Amsterdam UMCAmsterdam, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests how a drug enters tumours in people with lung or neuroendocrine cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
15 May 2026